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                     INTRODUCTION 
Primary hypothyroidism is the condition resulting from the inherent 
inability of the thyroid gland to supply a sufficient amount of the hormone. 
Overt hypothyroidism and atherosclerotic cardiovascular disease(1–3) is 
undoubtedly associated, but there is controversy whether this association is 
also present in subclinical hypothyroidism(2,4,5). Most studies in subclinical 
hypothyroidism show comparable but less pronounced associations(6,7). The 
association of thyroid disease with atherosclerotic cardiovascular disease 
may in part be explained by thyroid hormone’s regulation of lipid 
metabolism and its effect on blood pressure (BP) 
Metabolic syndrome also known as Syndrome X(8), Deadly Quartet(9), 
Insulin resistance Syndrome(10,11) consists of a constellation of metabolic 
abnormalities like central obesity, atherogenic dyslipidemia (elevated 
triglycerides and apolipoprotein B, small LDL particles and low HDL 
cholesterol [HDL-C] concentrations) ,elevated blood pressure, elevated 
plasma glucose, that confers increased risk of cardiovascular disease (CVD).  
People with metabolic syndrome are twice as likely to die from and three 
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times as likely to have a heart attack or stroke compared with people without 
the syndrome(1).  
As hypothyroidism is associated with  parameters like obesity(12)(13), 
hypertension(13-17),decreased HDL(18)(19) and elevated triglycerides(20)(21), it 
may be associated with metabolic syndrome.  
The study done by Aneemieke Ross et al. , reveals that free T4 was 
significantly related to four of five components of the metabolic syndrome 
(abdominal obesity, triglycerides, high-density lipoprotein cholesterol, and 
blood pressure), independent of insulin resistance(20). The study done by Lin 
ST et al found that lower serum free thyroxine level are associated with 
metabolic syndrome in a Chinese population(22). In a study from Nepal, 
Chandra L et al. found that metabolic syndrome was prevalent in 21. 1% of 
thyroid dysfunction patients(23).  
Poor drug compliance is common in chronic illness like diabetes, 
hypertension, dyslipidemia, hypothyroidism etc, irrespective of income and 
educational status of the patient. The study conducted by Mohan et al. 
among the industrial population of south India which provides free health 
care, reveals that among subjects receiving medication, only 42.1% of 
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subjects with diabetes and 55.3% of subjects with hypertension had their 
disease under adequate control(24). One of the reason for this may be because 
most of the people are unaware of the complications arising from inadequate 
control of disease.  
Coronary artery atherosclerosis is twice as common in patients with 
hypothyroidism compared with sex and age-matched controls, and adequate 
thyroid hormone replacement therapy may protect against the 
progression(25). In South East Asia the prevalence of diabetes, premature 
coronary artery disease and dyslipidemia are higher than the rest of the 
world due to rapid changes in demography, economic development(26,27) and 
partly to genetic predisposition(28-30). Frankly hypothyroid patients with poor 
drug compliance, Sub clinical hypothyroidism who are not started on 
levothyroxine as well as late diagnosis of hypothyroidism may have 
increased risk of metabolic syndrome. As no information is available from 
Indian literature regarding the prevalence of metabolic syndrome in 
hypothyroid patients, this study was undertaken.  
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           AIMS AND OBJECTIVES 
 
1) To study the prevalence of metabolic syndrome in female 
primary hypothyroidism either frankly hypothyroid patients not 
taking levothyroxine for more than 3 months, sub clinical 
hypothyroidism not started on levothyroxine as well as newly 
detected hypothyroidism not started on levothyroxine.  
2) To find out the association of hypothyroidism and Metabolic 
syndrome.  
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REVIEW OF LITERATURE 
ANATOMY AND DEVELOPMENT OF THYROID GLAND 
The thyroid name was derived from Greek (thyreos- shield, eidos-
form). It consists of two lobes that are connected by an isthmus. It is located 
anterior to the trachea between the cricoid cartilage and the suprasternal 
notch. The normal thyroid is 12–20 g in size . The thyroid gland develops 
from the floor of the primitive pharynx during the third week of gestation. 
The developing gland migrates along the thyroglossal duct to reach its final 
location in the neck.  
THYROID HORMONES 
The principal hormones secreted by the thyroid are thyroxine (T4) 
and triiodothyronine (T3). T3 is also formed in the peripheral tissues by 
deiodination of T4. Small amounts of reverse triiodothyronine (3,3´,5´-
triiodothyronine, RT3) and other compounds are also found in thyroid. T3 is 
more active than T4, whereas RT3 is inactive. The thyroid gland maintains 
the level of metabolism in the tissues that is optimal for their normal 
function.  
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MECHANISM OF ACTION   
Thyroid hormones enter cells, and T3 binds to thyroid receptors (TR) 
in the nuclei. T4 can also bind, but not as avidly. The hormone-receptor 
complex then binds to DNA via zinc fingers and increases or in some cases 
decreases the expression of a variety of different genes that code for 
enzymes which regulate cell function.  
THYROID AXIS 
TSH, secreted by the thyrotrope cells of the anterior pituitary, plays a 
pivotal role in control of the thyroid axis and serves as the most useful 
physiologic marker of thyroid hormone action. TSH is a 31-kDa hormone. 
Beta subunit is unique to TSH. The thyroid axis is a classic example of an 
endocrine feedback loop. Thyroid hormones are the dominant regulator of 
TSH production. TSH levels change dynamically in response to alterations 
of T4 and T3   
PRIMARY HYPOTHYROIDISM  
Primary hypothyroidism is the condition resulting from the inherent 
inability of the thyroid gland to supply a sufficient amount of the hormone.  
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PREVALENCE OF HYPOTHYROIDISM 
Overt hypothyroidism affects approximately 3% of the adult female 
Population(31) . It is estimated that as many as 7% to 10% of older women 
have subclinical hypothyroidism(7). 
CAUSES OF HYPOTHYROIDISM  
Hypothyroidism may be due to primary disease of the thyroid gland 
itself or lack of pituitary TSH. Iodine deficiency remains the most common 
cause of hypothyroidism worldwide. In areas of iodine sufficiency, 
autoimmune disease (Hashimoto's thyroiditis) and iatrogenic causes 
(treatment of hyperthyroidism) are most common   
PRIMARY  
Autoimmune Hypothyroidism:  
• Hashimoto's thyroiditis, atrophic thyroiditis  
Iodine deficiency 
Iatrogenic:  
• 
131I treatment, subtotal or total thyroidectomy, external  
irradiation of neck for lymphoma or cancer  
Drugs: 
• Iodine excess (including iodine-containing contrast media and 
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amiodarone),lithium, antithyroid drugs, p-aminosalicyclic acid, 
interferon- alpha and other cytokines,aminoglutethimide  
Congenital:  
• Absent or ectopic thyroid gland, dyshormonogenesis, TSH-R 
mutation. 
Infiltrative disorders:  
• Amyloidosis, sarcoidosis, hemochromatosis, scleroderma, 
cystinosis, Riedel's thyroiditis 
Over expression of type 3 deoiodinase in infantile hemangioma 
TRANSIENT 
• Silent thyroiditis, including postpartum thyroiditis  
• Subacute thyroiditis 
• Withdrawal of thyroxine treatment in individuals with an intact 
thyroid 
• After 131I treatment or subtotal thyroidectomy for Graves' 
disease 
SECONDARY 
• Hypopituitarism: tumors, pituitary surgery or irradiation, 
infiltrative disorders, Sheehan's syndrome, trauma, genetic 
forms of combined pituitary hormone deficiencies 
• Isolated TSH deficiency or inactivity 
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• Bexarotene treatment 
• Hypothalamic disease: tumors, trauma, infiltrative disorders, 
idiopathic 
INFLUENCE OF HYPOTHYROIDISM ON CARDIOVASCULAR FACTORS(32) 
Risk Factors Effect Evidence 
Lipids Increased total and LDL cholesterol A 
Blood pressure Diastolic hypertension  A 
Smoking  Impaired thyroid hormone actions  B 
Homocysteinemia  Mild increase  A 
Endothelium Endothelial dysfunction  C 
CRP Mild increase in moderate and severe 
hypothyroidism 
 C 
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SYMPTOMS OF HYPOTHYROIDISM 
 (Descending Order of Frequency)   
• Tiredness, weakness 
• Dry skin 
• Feeling cold 
• Hair loss 
• Difficulty concentrating and poor memory 
• Constipation 
• Weight gain with poor appetite 
• Dyspnea 
• Hoarse voice 
• Menorrhagia (later oligomenorrhea or amenorrhea) 
• Paresthesia  
• Impaired hearing 
SIGNS 
• Dry coarse skin; cool peripheral extremities 
• Puffy face, hands, and feet (myxedema) 
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• Diffuse alopecia 
• Bradycardia 
•  Peripheral edema 
•  Delayed tendon reflex relaxation 
•  Carpal tunnel syndrome 
•  Serous cavity effusions 
 LABORATORY EVALUATION 
a) Measurement of Thyroid Hormones 
Because TSH levels change dynamically in response to alterations of 
T4 and T3, a logical approach to thyroid testing is to first determine whether 
TSH is suppressed, normal, or elevated. The finding of an abnormal TSH 
level must be followed by measurements of circulating thyroid hormone 
levels to confirm the diagnosis of hypothyroidism. Unbound hormone are 
preferable to those for total thyroid hormones as numerous factors 
(illness,medications, genetic factors) can influence protein binding.  
Total thyroid hormone levels are elevated, 
When TBG is increased (due to pregnancy, oral contraceptives, 
hormone therapy, tamoxifen).  
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Total thyroid hormone levels are decreased, 
When TBG binding is reduced (androgens, nephrotic syndrome).        
Genetic disorders and acute illness can also cause abnormalities in 
thyroid hormone binding proteins, and various drugs [phenytoin, 
carbamazepine, salicylates, and nonsteroidal anti-inflammatory drugs 
(NSAIDs)] can interfere with thyroid hormone binding. Because unbound 
thyroid hormone levels are normal and the patient is euthyroid in all of these 
circumstances.  
b) TPO antibodies  
TPO antibodies present in >90% of patients with autoimmune 
hypothyroidism and up to 80% of those with Graves' disease.                                                                             
c)       Radioiodine uptake and thyroid scanning 
d) Thyroid Ultrasound 
e) Fine-needle aspiration (FNA) biopsy 
f)  Other abnormal laboratory findings 
May include, increased creatine phosphokinase, elevated cholesterol 
and triglycerides, and anemia (usually normocytic or macrocytic). Except 
when accompanied by iron deficiency, the anemia and other abnormalities 
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gradually resolve with thyroxine replacement.  
MANAGEMENT 
Levothyroxine (thyroxine; T4) is the treatment of choice. It is partially 
converted in the body to T3, the more active thyroid hormone. If there is no 
residual thyroid function, the daily replacement dose of levothyroxine is 
usually 1. 6 g/kg body weight (typically 100–150 g). In many patients, 
however, lower doses suffice until residual thyroid tissue is destroyed.  
Adult patients under 60 without evidence of heart disease may be started on 
50-100g levothyroxine (T4) daily. The dose is adjusted on the basis of TSH 
levels, with the goal of treatment being a normal TSH, ideally in the lower 
half of the reference range. TSH responses are gradual and should be 
measured about 2 months after instituting treatment or after any subsequent 
change in levothyroxine dosage  
SUBCLINICAL HYPOTHYROIDISM 
By definition, subclinical hypothyroidism refers to biochemical 
evidence of thyroid hormone deficiency in patients who have few or no 
apparent clinical features of hypothyroidism. It is estimated that as many as 
7% to 10% of older women have subclinical hypothyroidism(7). Although 
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subclinical disease is frequently “asymptomatic,” many patients have 
symptoms of thyroid hormone deficiency(33,34). Lipid metabolism is altered 
in subclinical hypothyroidism(4,35). Patients have increased serum lipid 
levels, and cholesterol levels appear to rise in parallel with serum TSH.(7,34) 
Impaired endothelium-dependent vasodilatation as a result of a reduction in 
nitric oxide availability has been demonstrated in subclinical hypothyroidism as 
well resulting in hypertension(36). 
SUBCLINICAL HYPOTHYROIDISM AND RISK FACTORS(32) 
Risk Factors Effect Evidence 
Lipids Mild increased in total and LDL 
Cholesterol Serum 
TSH 4.5–10 
mU/L- C 
Blood pressure Mild increase in diastolic pressure C 
Homocysteine None B 
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METABOLIC SYNDROME 
The metabolic syndrome also known as (syndrome X(8), ‘Deadly 
Quartet’(9) insulin resistance Syndrome(10,11).  
Metabolic syndrome consists of multiple, interrelated risk factors of 
metabolic origin that appear to directly promote the development of 
atherosclerotic cardiovascular disease (ASCVD) and strongly associated 
with type 2 diabetes mellitus(37)  
EPIDEMIOLOGY 
Prevalence of the metabolic syndrome varies across the globe. In 
general, the Prevalence of metabolic syndrome increases with age. The 
metabolic syndrome was present in 22.8% and 22.6% of US men and 
women(37) meeting National Cholesterol Education Program, Adult 
Treatment Panel III (NCEP:ATPIII) criteria. The metabolic syndrome was 
present in 4. 6%, 22.4% and 59.6% of normal weight, overweight and obese 
men respectively and similar distribution found in women(38). Older age, 
high body mass index, current smoking, low household income, high 
carbohydrate diet and physical inactivity were associated with increased risk 
of Metabolic syndrome.  
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PREVALENCE OF METABOLIC SYNDROME IN INDIA: 
Mohan et al. in CURES-34 study found the prevalence of MS was 23. 
2% by WHO criteria, 18.3% by ATPIII criteria and 25.8% by IDF 
criteria(39). Study done by Ramachandran et al. shows prevalence of 
Metabolic syndrome in urban Asian adults was 41.1% based on modified 
ATP III Criteria. WC was increased in 31. 4%, TG in 45.6%, low HDL-C in 
65.5%, hypertension in 55.4% and raised FPG 26.7%. Metabolic syndrome 
was more common in women than in men and in older people(40). Study by 
Gupta et al. revealed the Prevalence (%) of cardiovascular risk factors in 
men and women, hypertension in 37.0 and 37.6, overweight and obesity in 
37.8 and 50.3, truncal obesity in 57.3 and 68.0, high cholesterol > 200mg/dl 
in 37.4 and 45.8, high triglycerides >150 mg/dl in 32.3 and 28. 6 and 
metabolic syndrome in 22.9 and 31.6%(41).  
“Whichever definition is used and whatever the variation in the 
numbers due to the different criteria, when looking at prevalence data for the 
metabolic syndrome in different countries and across various ethnic groups, 
one fact is clear. Universally, the metabolic syndrome is a huge problem  
and is one that is growing at an alarming rate”.                                 
Professor Sir George Alberti, co-author of the Consensus Statement(42) 
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DIAGNOSIS OF  
METABOLIC SYNDROME 
Although Reaven(8) already highlighted the concepts of insulin 
resistance and the metabolic syndrome in 1988, it lasted until 1998(42) before 
the first attempt for an internationally accepted definition was put forward.  
WHO CLINICAL CRITERIA FOR METABOLIC SYNDROME(43) 
Glucose intolerance, impaired glucose tolerance (IGT) or diabetes 
and/or insulin resistance, together with two or more of the following 
components: 
• Central obesity (males: waist to hip ratio > 0. 90; females: waist 
to hip ratio >0. 85) and/or BMI > 30 kg/m2 
• Raised plasma triglycerides (≥ 1.7 mmol/L; 150 mg/dL) and/or 
low HDL cholesterol (< 0.9 mmol/L, 35 mg/dL men; < 1.0 
mmol/L, 39 mg/dL women) 
• Raised Blood pressure ≥ 140/90 mm Hg 
• Microalbuminuria (urinary albumin excretion rate ≥ 20g/min or 
albumin:creatinine ratio ≥ 30 mg/g) 
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ATP III CRITERIA FOR METABOLIC SYNDROME (44) 
Three or more of the following five risk factors: 
• Central obesity: Waist circumference for men > 102 cm          
(> 40 in )Women > 88 cm (>35 in) 
• Triglycerides ≥ 150 mg/dL (1.7 mmol/L) 
• HDL cholesterol 
Men < 40 mg/dL (1.03 mmol/L) 
Women < 50 mg/dL (1.29 mmol/L) 
• Blood pressure ≥ 135/ ≥ 85 mm Hg 
• Fasting glucose ≥ 6.1 mmol/L 
AHA/NHLBI CRITERIA FOR METABOLIC SYNDROME 2005(37) 
Three or more of the following five risk factors: 
• Central obesity: Waist circumference for men > 102 cm (>40in) 
Women > 88cm (> 35 in) 
-Modified WC for South Asians- Male ≥ 90 cm, Female ≥ 80 cms 
• Triglycerides ≥ 150 mg/dL (1. 7 mmol/L) 
• HDL cholesterol 
Men < 40 mg/dL (1. 03 mmol/L) 
Women < 50 mg/dL (1. 29 mmol/L) 
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• Blood pressure ≥ 130/ ≥ 85 mm Hg 
• Fasting glucose ≥ 100 mg/dl 
THE NEW INTERNATIONAL DIABETES FEDERATION(IDF) 
DEFINITION(42) 
Central obesity defined as the waist circumference for South Asians: 
Male ≥ 90 cms Female ≥ 80 cms 
Plus any two of the following four factors: 
• Raised TG level: ≥ 150 mg/dL (1.7 mmol/L), or specific 
treatment for this lipid abnormality 
• Reduced HDL cholesterol: <40 mg/dL (1.03 mmol/L) in 
males and < 50 mg/dL (1.29 mmol/L)  in females, or specific 
treatment for this lipid abnormality. 
• Raised blood pressure:  systolic BP ≥ 130 or diastolic BP ≥ 
85 mm Hg, or treatment of  previously diagnosed hypertension 
• Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5. 6 
mmol/L), or previously diagnosed type 2 diabetes 
PATHOPHYSIOLOGY OF THE METABOLIC SYNDROME 
The central pathophysiological phenomenon underlying the clustering 
is Insulin Resistance(45). Major contributor to the development of insulin 
resistance is an overabundance of circulating fatty acids derived 
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predominantly from adipose tissue triglyceride stores released by hormone-
sensitive lipase. Fatty acids are also derived through the lipolysis of 
triglyceride-rich lipoproteins in tissues by lipoprotein lipase (LPL). Insulin 
mediates both antilipolysis and the stimulation of LPL in adipose tissue 
INCREASED WAIST CIRCUMFERENCE 
With increases in visceral adipose tissue, adipose tissue-derived FFAs 
are directed to the liver. On the other hand, increases in abdominal 
subcutaneous fat release lipolysis products into the systemic circulation and 
avoid more direct effects on hepatic metabolism.  
DYSLIPIDEMIA 
FFA flux to the liver is associated with increased production of apoB–
containing, triglyceride- rich very low density lipoproteins (VLDLs). 
Hypertriglyceridemia is an excellent marker of the insulin-resistant 
condition. Reduction of HDL cholesterol is a consequence of changes in 
HDL composition and metabolism. In the presence of hypertriglyceridemia 
decrease in the cholesterol content of HDL is a consequence of reduced 
cholesteryl ester content of the lipoprotein core in combination with 
cholesteryl ester transfer protein–mediated alterations in triglyceride making 
the particle small and dense. This change in lipoprotein 
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composition also results in an increased clearance of HDL from the 
circulation.                                                                                
HYPERTENSION                                                                                                                                                                                                                                     
In the setting of insulin resistance, the vasodilatory effect of insulin is lost, 
but the renal effect on sodium reabsorption is preserved. Insulin also 
increases the activity of the sympathetic nervous system, an effect that may 
also be preserved in the setting of the insulin resistance. Finally, insulin 
resistance is characterized by pathway-specific impairment in 
phosphatidylinositol 3-kinase signaling. In the endothelium, this may cause 
an imbalance between the production of nitric oxide and secretion of 
endothelin-1, leading to decreased blood flow.  
GLUCOSE INTOLERANCE 
 The defects in insulin action lead to impaired suppression of glucose 
production by the liver and kidney and reduced glucose uptake and 
metabolism in insulin-sensitive tissues, i.e., muscle and adipose tissue. To 
compensate for defects in insulin action, insulin secretion and/or clearance 
must be modified to sustain euglycemia. Ultimately, this compensatory 
mechanism fails and progress from IFG and/or IGT to DM.  
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PROINFLAMMATORY CYTOKINES 
 The increases in proinflammatory cytokines, including IL-1,IL-6,IL-
18, tumor necrosis factor (TNF alpha) and C-reactive protein (CRP), reflect 
overproduction by the expanded adipose tissue mass . Adipose tissue-
derived macrophages may be the primary source of pro-inflammatory 
cytokines. FFAs also increase the hepatic production of fibrinogen and 
adipocyte production of plasminogen activator inhibitor 1 (PAI-1), resulting 
in a prothrombotic state. Higher levels of circulating cytokines also stimulate 
the hepatic production of C-reactive protein (CRP) 
 ADIPONECTIN  
 Adiponectin is an anti-inflammatory cytokine produced exclusively 
by adipocytes. It enhances insulin sensitivity and inhibits many steps in the 
inflammatory process. In the liver, adiponectin inhibits the expression of 
gluconeogenic enzymes and the rate of glucose production. In muscle, 
adiponectin increases glucose transport and enhances fatty acid oxidation, 
partially due to activation of AMP kinase. Adiponectin is reduced in the 
metabolic syndrome .  
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MANAGEMENT OF METABOLIC SYNDROME(37,42,) 
•  Primary intervention 
Healthy lifestyle promotion which includes: 
• Moderate calorie restriction (to achieve a 5–10 per cent loss of 
body weight in the first year) 
• Moderate increase in physical activity 
• Change in dietary composition 
•  Secondary intervention 
In people for whom lifestyle change is not enough and who are 
considered to be at high risk for CVD, drug therapy may be required to treat 
the metabolic syndrome. While mechanisms underlying metabolic syndrome  
are currently unknown and specific pharmacological agents are therefore not 
yet available, it is currently recommended to treat the individual components 
of the syndrome in order to reduce the CVD and diabetes risk.  
Selective CBI-receptor blockade drugs like Rimonabant significantly 
reduces the several metabolic risk factors in metabolic syndrome(46,47) 
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HYPOTHYROIDISM AND OBESITY 
Thyroid function could be one of several factors acting in concert to 
determine body weight in a population. In a study of elderly subjects, a 
possible association between mild hypothyroidism and BMI was found 
among women(48). Even slightly elevated serum TSH levels are associated 
with an increase in the occurrence of obesity(12). Leptin produced by 
adipocytes has important influences on central regulation of thyroid function 
through stimulation of TRH. This seems to be important for down-regulation 
of thyroid function in states of energy deficits . Leptin levels are decreased 
in the hypothyroid patients. Whether decreased leptin levels may contribute 
to the decreased energy expenditure in patients with hypothyroidism merits 
further investigation(49-52). It has been suggested that thyroid hormones may 
be a significant determinant of sleeping energy expenditure also in subjects 
without overt thyroid dysfunction(53). Prolonged decrease in REE might well 
lead to increased body weight in he current environment of food plenty and 
physical inactivity.  
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HYPOTHYROIDISM AND DYSLIPIDEMIA 
 Even in the euthyroid range, TSH was positively associated with 
HDL-C, TG, and Apo A-I(20). The elevation of TGs in hypothyroidism is 
caused by a reduced removal rate of TG from plasma due to a decrease in 
the activity of hepatic TG lipase(54). Some studies have shown that 
hypothyroidism is associated with a lower HDL cholesterol level. Althaus et 
al(55),Caron et al(56) found a significantly lower HDL cholesterol fraction 
even in the subclinically hypothyroid patients. Furthermore, Caron et al. 
observed a significant increase in the HDL cholesterol level with T4 therapy, 
which normalized the serum TSH concentration.  
 Elevated levels of total cholesterol, LDL cholesterol, and 
apolipoprotein are well documented features of overt hypothyroidism (57,58). 
Early studies in humans with hypothyroidism, using isotopically labeled 
LDL,demonstrated a prolonged half-life of LDL cholesterol because of 
decreased catabolism, an effect that was reversible with T4 therapy(59). T4 
therapy in overt hypothyroidism is standard practice, controversy exists 
regarding the indications for therapy in subclinical hypothyroidism. One 
rationale for treating subclinical hypothyroidism is to lower levels of LDL 
cholesterol and thereby decrease atherosclerotic risk. Multiple small, 
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randomized trials have been performed examining the effect of T4 treatment 
on lipid parameters in subclinical hypothyroidism, with the majority 
reporting a tendency toward beneficial effects, without achieving statistical 
significance(60). Studies have also shown that hypothyroidism causes 
qualitative changes in circulating lipoproteins that increase their 
atherogenicity. Two studies have shown that LDL is more susceptible to 
oxidation in patients with hypothyroidism, with normalization after 
restoration of the euthyroid state(61,62). Several studies have shown decreases 
in the Lp(a) concentration after T4 treatment of hypothyroid patients(63-66). 
However, other reports have not confirmed this relationship(67,68). Clinical 
trials have not demonstrated an effect of T4 on Lp(a) levels in subclinical 
hypothyroidism(66-70), with the exception of one trial, which showed a 
decrease in Lp(a)(71). Additional potentially atherogenic effects of 
hypothyroidism on lipid metabolism include a reversible reduction in 
clearance of chylomicron remnants(72); reduced activity of cholesteryl ester 
transfer protein, which is involved in reverse cholesterol transport pathway 
(73,74); and decreased activity of hepatic lipase(75,76) and lipoprotein lipase(75). 
HYPOTHYROIDISM AND HYPERTENSION 
 Potential mechanisms for reversible diastolic and systolic 
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hypertension in hypothyroidism include increases in peripheral vascular 
resistance and arterial stiffness(77) respectively. In hypothyroidism, arterial 
compliance is reduced, which leads to increased SVR. In hypothyroidism, 
endothelial dysfunction and impaired VSM relaxation lead to increased 
SVR(78). These effects lead to diastolic hypertension in approximately 30% 
of patients, and thyroid hormone replacement therapy restores endothelial-
derived vasorelaxation and blood pressure to normal in most(36). 
Vasoconstriction may, in turn, reflect the absence of demonstrated 
vasodilatory T3 effects on vascular smooth muscle(79) or be the result of a 
higher circulating noradrenaline level and a decrease in the number of 
vascular beta adrenergic receptors mediating vasodilatation in skeletal 
muscle(16). In addition, type II iodothyronine deiodinase has been found in 
cultured human coronary artery smooth muscle cells and human aortic 
smooth muscle cells, suggesting a potential direct role of local T3 on 
vascular smooth muscle(1,80). The increase in diastolic pressure occurs with 
low serum renin levels(81)and is a sodium sensitive form of hypertension(82). 
Asvold et al. report a linear correlation between TSH and both systolic and 
diastolic blood pressure(14), whereas other studies do not find a 
correlation(17,31,83). In one study of 169 women with overt hypothyroidism, 
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the prevalence of hypertension was nearly 3 times higher than in a euthyroid 
control group(14.8% vs. 5.5%)(16). Euthyroid normotensive patients in 
another report had an increase in diastolic blood pressure after 
thyroidectomy-induced hypothyroidism(5), and hypertension was reversed by 
T4 treatment.  There is less published evidence regarding subclinical 
hypothyroidism and hypertension. Luboshitzky et al. did observe that mean 
diastolic blood pressure was higher in subclinical hypothyroidism(84). 
Impaired endothelium-dependent vasodilatation as a result of a reduction in 
nitric oxide availability has been demonstrated in subclinical 
hypothyroidism as well(36). 
HYPOTHYROIDISM AND DIABETES 
Glucose intolerance in hypothyroidism is not proved in latest studies 
though Shah et al. published insulin metabolism in hypothyroidism in 1975 
indicating that glucose intolerance of the hypothyroid state is not 
characterized by insulin resistance(85). Aneemieke Ross et al. in 2007 found 
that free T4 was significantly associated with insulin resistance and with 
four of five components of the metabolic syndrome (except glucose 
intolerance)(20). 
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MATERIAL AND METHODS 
Setting 
The study was conducted in the Endocrinology OPD, Department of 
Endocrinology, Institute of Internal Medicine, Madras Medical College and 
Government General Hospital, Chennai.  
Collaboration Department 
Endocrinology OPD, Institute of Internal Medicine.  
Ethical Approval 
Institute Ethical Committee approved the study.  
Study Design 
       Single Centre 
Non randomized cross sectional study.  
Study Period 
Study was conducted between December 2007 and September 2008 
for a period of 10 months.  
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Sample Sizes 
 In the study period of 10 months female hypothyroid patients 
attending the Endocrinology OPD,Institute of Internal Medicine after 
applying inclusion and exclusion criteria, 55 patients were included in the 
study.  
Selection of Study Subjects   
The female primary hypothyroid patient in the age group of 21-55 
were eligible for the study. Clinically hypothyroid patient with poor drug 
compliance who had discontinued levothyroxine for the period of over 3 
months, Subclinical hypothyroidism not started on levothyroxine as well as 
newly diagnosed hypothyroidism not started on levothyroxine were taken 
into study. It is confirmed that they had not taken levothyroxine for 3 
months by detail history.  
 Inclusion Criteria 
• Female Sex.  
• Age group between 21-55 years.  
• Clinically hypothyroid patient who had discontinued 
Levothyroxine for period of over 3 months.  
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• Newly detected hypothyroidism who had not started on 
levothyroxine.  
• Subclinical hypothyroidism not started on Levothyroxine.  
• Non Smokers,Non alcoholic.  
Exclusion Criteria 
• Male sex, pregnant women.  
• Age below 21 years or above 55 years.  
• Smoker, Alcoholic.  
• Primary hypothyroid patient taking levothyroxine < 3 months.  
• Severely ill patient.  
• Patient taking medication for Diabetes, Hypertension, lipid 
disorder .  
• Patient taking steroids.  
• Known metabolic syndrome patients.  
Consent 
• All participants gave written informed consent.  
METHODOLOGY 
Detailed history including medication, smoking, alcohol intake 
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anthropometric measurements like height, weight, waist circumference were 
noted in a semi structured proforma. Thyroid hormone assay was performed. 
It was confirmed that they had not taken levothyroxine for the previous 3 
months. Waist circumference was measured keeping tape in a horizontal 
plane around the abdomen at level of iliac crest. Blood Pressure was 
recorded in sitting position in the right arm, with a mercury 
sphygmomanometer (Diamond BP apparatus, Pune, India). After eight hours 
of fasting, blood was drawn for fasting blood sugar lipid profile in a single 
sitting.  
 The fasting blood sugar was done by enzymatic method(Glucose 
Oxidase peroxidase) using fully automated analyzer. The lipid profile(Total 
cholesterol,HDL,Triglycerides) was done enzymatically on XL-300 ERBA 
fully automated clinical chemistry analyzer. LDL was calculated by the 
formula, 
 LDL=Total Cholesterol-HDL-(Triglceride/5) 
 Thyroid hormone assay was done by Radio Immuno Assay(RIA) or 
Indirect Radio Immunoassay(IRMA) using ADVIA centaur Bayer Health 
care.  
 39
DEFINITIONS 
Primary Hypothyroidism: 
Inherent inability of the thyroid gland to supply a sufficient amount of 
the hormone most commonly due to the destruction of the thyroid gland by 
disease or as a consequence of vigorous ablative therapies.  
Clinical or overt Hypothyroidism: 
Patient with few or apparent clinical features of hypothyroidism with 
biochemical evidence of thyroid hormone deficiency  
Subclinical Hypothyroidism: 
Patients who have few or no apparent clinical features of 
hypothyroidism with biochemical evidence of thyroid hormone deficiency.  
Thyroid function tests-Normal values: 
Serum T3(Total)  =  0. 7-2.0 ng/ ml  
Serum T4(Total) =  5. 5-13. 5 µg/dl  
Serum TSH         = 0. 17-4. 05 uIU/ml  
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THE NEW INTERNATIONAL DIABETES FEDERATION (IDF) 
DEFINITION(42) 
Central obesity defined as the wiast circumference for South Asians: 
Male ≥ 90 cms Female ≥ 80 cms 
Plus any two of the following four factors: 
• Raised TG level: ≥150 mg/dL (1.7 mmol/L), or specific 
treatment for this lipid abnormality 
• Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males 
and <50 mg/dL (1.29 mmol/L)  in females, or specific treatment 
for this lipid abnormality 
• Raised blood pressure:  systolic BP ≥ 130 or diastolic BP ≥ 85 
mm Hg, or treatment of  previously diagnosed hypertension 
• Raised fasting plasma glucose (FPG) ≥100 mg/dL (5.6 
mmol/L), or previously diagnosed type 2 diabetes 
AHA/NHLBI CRITERIA FOR METABOLIC SYNDROME (37) 
Three or more of the following five risk factors: 
• Central obesity: Waist circumference for men > 102 cm (> 40 
in )Women > 88 cm (> 35 in) Modified WC for south asians- 
Male ≥ 90 cm, Female ≥ 80 cms 
• Triglycerides ≥ 150 mg/dL (1. 7 mmol/L) 
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• HDL cholesterol  
Men < 40 mg/dL (1.03 mmol/L) 
Women < 50 mg/dL (1.29 mmol/L) 
• Blood pressure ≥ 130/ ≥ 85 mm Hg 
• Fasting glucose ≥ 100 mg/dl 
 STATISTICAL ANALYSIS 
SPSS12 and Excel were used for data analysis.  
LIMITATIONS 
• Small number of study subjects.  
• No control subjects 
•  Cross sectional study 
CONFLICT OF INTEREST 
• Nil conflict of interest 
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RESULTS AND OBSERVATION 
 TABLE-1 POPULATION CHARACTERISTICS 
  TOTAL NO OF PATIENTS: 55 
AGE  NO OF PATIENTS PERCENTAGE(%) 
<30 14 25. 45 
30-40 20 36. 36 
>40 21 38. 18 
P value > 0. 05 Not significant at 5% level 
POPULATION CHARACTERISTICS: 
 55 Patients were included in our study in the age group between 21 
and 55. Patient below 30 were 14 (25.45%) in number. Majority of the 
patients were above 40 age group and constitutes 38.18% (21 in number).  
20 patients were between 30-40 (36.36%). Population characteristics are 
shown in Table 1. Distribution was statistically not significant 
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TABLE -2 DISTRIBUTION OF HYPOTHYROID PATIENTS 
 TOTAL NO OF PATIENTS: 55 
HYPOTHYROID TOTAL 
NO 
PERCENTAGE 
(%) 
Newly detected 
 Clinical   8 
 Subclinical   8 
16 29. 09 
Clinical hypothyroidism not on levothyroxine 
> 3 Months  
23 41. 82 
Subclinical hypothyroidism not on 
levothyroxine 
16 29. 09 
 P value > 0. 05 Not significant at 5% level 
Among the 55 patient included in our study, 16 patients(29.09%) were 
newly detected primary hypothyroid. In newly detected patients, 8 patients 
had clinical hypothyroidism while 8 were subclinical hypothyroidism.  
Clinically hypothyroid patient who had not taken levothyroxine 
>3months were majority with 23(41.82%) in number. Sub clinical 
hypothyroidism not on levothyroxine constituted the rest with 16 in number 
29.09%.  They are statistically not significant (>0.05%) at 5% level.  
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PREVALENCE OF METABOLIC SYNDROME  
TABLE-3 METABOLIC SYNDROME AS PER AHA/NHLBI 2005 
CRITERIA 
FACTORS NO OF PATIENTS PERCENTAGE(%) 
≥ 3 27 49. 09 
<3 28 50. 91 
 P value > 0. 05 Not significant at 5% level 
Among 55 patients 27 patients were diagnosed to have metabolic 
syndrome(≥ 3 parameters). They constitute 49. 09% of the study population.  
TABLE-4 METABOLIC SYNDROME AS PER IDF CRITERIA  
METABOLIC SYNDROME NO OF PATIENTS PERCENTAGE(%) 
 PRESENT 22 40 
 ABSENT 33 60 
 P value > 0. 05 Not significant at 5% level 
Among 55 patients 22 patients were diagnosed to have metabolic 
syndrome(central obesity plus any 2 of the 4 parameters). They constituted 
40% of the study population.  
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TABLE - 5  DISTRIBUTION OF METABOLIC SYNDROME IN 
HYPOTHYROID PATIENTS: 
 TOTAL NO OF PATIENTS: 55 
HYPOTHYROID PATIENTS 
NO OF METABOLIC 
SYNDROME PATIENTS  
AS PER AHA/NHLBI 2005 
CRITERIA  
n-27 
NO OF METABOLIC 
SYNDROME PATIENTS  
AS PER IDF CRITERIA 
n-22 
Newly detected 
n-16 
7(43. 75%) 5(31. 25%) 
Subclinical 
hypothyroidism not on 
levothyroxine 
 n-16 
 
10(62. 5%) 
 
9 (56. 25%) 
Clinical hypothyroidism 
not on levothyroxine > 
3 Months  
 n-23  
 
10(43. 48%) 
 
8 (34. 78%) 
 P value > 0. 05 Not significant at 5% level 
 62.5% and 56. 5%of the total Sub clinical hypothyroid patients not on 
levothyroxine had Metabolic syndrome as per AHA/NHABI criteria and IDF 
criteria respectively.  
There was no statistically significant increase of Metabolic syndrome 
in one group in our study. 
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TABLE- 6 AGE DISTRIBUTION OF METABOLIC SYNDROME 
AGE NO OF METABOLIC SYNDROME 
PATIENTS AS PER AHA/NHLBI 
2005 CRITERIA 
NO OF METABOLIC 
SYNDROME PATIENTS AS 
PER IDF CRITERIA 
 <30 4 2 
 30-40 6 6 
 >40 17 14 
                               s                       P = 0. 01 Significant at 5% level 
Above 40 yrs Metabolic syndrome was diagnosed in 17 patients 
which constitutes 80.95% (AHA/NHLBI 2005 criteria) and in 14 patients 
which constitutes 66.66% (IDF criteria). Below 30 age group only 4 patients 
as per AHA/NHLBI 2005 criteria (28.57%) and 2 patient(14.26%)as per IDF 
criteria.  
The prevalence increased with age and was statistically significant.  
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OBESITY IN HYPOTHYROIDISM 
TABLE-7 WAIST CIRCUMFERENCE IN HYPOTHYROIDISM 
WAIST 
CIRCUMFERENCE  
in cms 
TOTAL NO OF 
PATIENTS 
PERCENTAGE(%) 
≥ 80 24 43. 64 
<80 31 56. 36 
 P value > 0.05 Not significant at 5% level 
43. 64% of the study group was having central obesity.  
TABLE-8  BODY MASS INDEX IN HYPOTHYROIDISM 
BMI in Kg/m2 TOTAL NO OF PATIENTS PERCENTAGE(%) 
 NORMAL <23 14 25. 45 
OVERWEIGHT 23-24. 9 7 12. 73 
OBESE ≥ 25 34 61. 82 
  P =0. 001 Significant at 5% level 
Majority of the patient were obese with 61.82% with BMI ≥ 25. Over 
weight patient with BM1 (23-24.9) were 7 in number.   
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DYSLIPIDEMIA IN HYPOTHYROIDISM 
 
TABLE- 9 TRIGLYCERIDE IN HYPOTHYROIDISM 
TRIGLYCERIDE in mgs TOTAL NO OF PATIENTS PERCENTAGE (%) 
 ≥ 150 33 60 
 <150 22 40 
 P value > 0. 05 Not significant at 5% level 
Nearly 60% of the study group were affected by hypertriglyceridemia 
(TG ≥ 150mgs).  
TABLE -10 HDL IN HYPOTHYROIDISM 
HDL in mgs TOTAL NO OF 
PATIENTS 
PERCENTAGE(%) 
<50 49 89. 09 
≥ 50 6 10. 91 
                                             P value < 0. 001 Significant at 5% level 
The most prevalent lipid abnormalities was reduced HDL (<50 mgs) 
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with 89.09% of the study group affected. 49 patients out of 55 patients are 
affected by this abnormality.  
TABLE -11 TOTAL CHOLESTEROL IN HYPOTHYROIDISM 
TOTAL CHOLESTEROL 
in mgs 
TOTAL NO OF 
PATIENTS 
PERCENTAGE (%) 
 ≥ 200 30 54.55 
 <200 25 45.45 
P value > 0.05 Not significant at 5% level 
Elevated cholesterol (≥ 200mgs) was seen in 54.55% of the study 
group.  
 TABLE - 12 LDL IN HYPOTHYROIDISM 
LDL in mgs 
TOTAL NO OF 
PATIENTS 
PERCENTAGE(%) 
 ≥ 130 24 43. 64 
 <130 31 56. 36 
                                     P value > 0.05 Not significant at 5% level 
Elevated LDL ≥ 130mgs was seen in 43. 64% of the study group.  
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HYPERTENSION IN HYPOTHYROIDISM 
TABLE–13 SYSTOLIC BLOOD PRESSURE IN HYPOTHYROIDISM 
SBP in mm of Hg 
TOTAL NO OF 
PATIENTS 
PERCENTAGE(%) 
≥ 130 18 32. 73 
<130 37 67. 27 
P=0. 01 Significant at 5% level 
TABLE-14 DIASTOLIC BLOOD PRESSURE IN HYPOTHYROIDISM 
DBP in mm of Hg 
TOTAL NO OF 
PATIENTS 
PERCENTAGE(%) 
≥ 85 18 32. 73 
 <85 37 67. 27 
P=0. 01 Significant at 5% level 
Both systolic and diastolic hypertension was seen in 32. 73% of the 
study group.  
TABLE- 15 IMPAIRED GLUCOSE TOLERANCE IN HYPOTHYROIDISM 
FBS in mgs TOTAL NO OF 
PATIENTS 
PERCENTAGE(%) 
≥ 100  26 47. 27 
<100 29 52. 73 
 P value > 0. 05 Not significant at 5% level  
Impaired glucose tolerance with fasting plasma glucose ≥ 100mgs was 
seen in 47. 27% of the study group.  
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TABLE-16  DISTRIBUTION OF METABOLIC SYNDROME 
PARAMETERS (AS PER AHA/NHLBI 2005 CRITERIA) IN 
HYPOTHYROIDISM 
METABOLIC SYNDROME 
NO METABOLIC 
SYNDROME 
MS 
PARAMETERS 
MEAN SD MEAN SD 
P 
VALUE 
WAIST  88. 44 8. 82 74. 61 6. 01 0. 001 
TG  260. 44 129. 60 137. 75 66. 73 0. 001 
HDL  40. 52 4. 53 44. 86 10. 12 0. 046 
SBP  130. 44 9. 91 118. 29 7. 79 0. 001 
DBP  84. 44 7. 07 76. 79 4. 50 0. 001 
FBG 116. 37 28. 99 91. 50 10. 81 0. 001 
BMI 28. 76 4. 20 23. 56 3. 37 0. 001 
TC 235. 74 53. 14 191. 46 47. 58 0. 002 
LDL 143. 13 50. 88 119. 06 46. 80 0. 07 
 
TABLE- 17 DISTRIBUTION OF METABOLIC SYNDROME 
PARAMETERS (AS PER IDF CRITERIA) IN 
HYPOTHYROIDISM 
METABOLIC SYNDROME 
NO METABOLIC 
SYNDROME MS 
PARAMETERS MEAN SD MEAN SD 
P 
VALUE 
WAIST 91. 50 6. 32 74. 67 5. 74 0. 001 
TG 276. 73 138. 39 145. 48 64. 78 0. 001 
HDL 40. 59 4. 04 44. 15 9. 75 0. 112 
SBP 132. 45 9. 19 118. 79 7. 87 0. 001 
DBP 85. 55 6. 87 77. 21 4. 82 0. 001 
FBG 118. 05 31. 84 94. 15 12. 09 0. 001 
BMI 29. 77 3. 79 23. 67 3. 29 0. 001 
TC 239. 23 55. 37 195. 85 47. 52 0. 003 
LDL 143. 29 53. 72 122. 60 46. 14 0. 113 
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Diagram 1: Distribution of Hypothyroid 
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Diagram 2: Age Distribution
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DISCUSSION 
Overt hypothyroidism affects approximately 3% of the adult female 
Population. It is estimated that as many as 7% to 10% of older women have 
subclinical hypothyroidism (7). The prevalence of hypothyroidism increases 
with age. As early as 1883, Kocher raised the hypothesis of a causal 
relationship between hypothyroidism and atherosclerosis (86).  
 Metabolic syndrome consists of multiple, interrelated risk factors of 
metabolic origin that appear to directly promote the development of 
atherosclerotic cardiovascular disease. The metabolic risk factors consist of 
atherogenic dyslipidemia (elevated triglycerides and apolipoprotein B, small 
LDL particles and low HDL cholesterol [HDL-C] concentrations), elevated 
blood pressure and elevated plasma glucose. The prevalence of metabolic 
syndrome is estimated to be around 20–25 per cent of the population. The 
prevalence of metabolic syndrome increases with the age.  
 As hypothyroidism is associated with parameters like obesity(12)(13), 
hypertension(13)(15-17), decreased HDL(18)(19), elevated triglycerides(20)(21), 
frankly hypothyroid patients with poor drug compliance, subclinical 
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hypothyroidism not on levothyroxine, late diagnosis of hypothyroidism may 
have increased risk of metabolic syndrome.  
Enas et al.(87) in his study found that South Asians develop metabolic 
abnormalities at a lower body mass index and waist circumference than 
other groups, conventional criteria underestimate the prevalence of MS by 
25% to 50%. South Asian-specific waist circumference recommended by the 
International Diabetes Federation appear to be more appropriate in this 
Population. So in our study waist circumference was adjusted to the south 
Asians.  
 In our study 22 patients (40%) and 27 patients(49.09%) of the study 
group were diagnosed to have metabolic syndrome as per IDF criteria (Waist 
circumference adjusted to the south Asians) and AHA/NHLBI 2005 
criteria(Waist circumference adjusted to the south Asians)respectively. High 
prevalence of Metabolic syndrome was noted in clinically hypothyroid 
patient with poor drug compliance, subclinical hypothyroidism not started 
on levothyroxine as well as newly diagnosed hypothyroid patient. There was 
no statistically significant difference in prevalence of metabolic syndrome 
between the three groups. It reveals that all the groups were affected equally.  
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 Metabolic syndrome was higher in study group than in the general 
population of this region. Mohan et al. in his CURES-34 study identified 
Metabolic syndrome in 23.2% by WHO criteria,18.3% by ATPIII criteria 
and 25.8% by IDF criteria in this region(88). Study by Mohan et al. in 
industrial Population found Metabolic syndrome in 34.1% using modified 
ATPIII criteria(24). Ramachandran et al. showed that the prevalence of 
Metabolic syndrome in Urban Asian adults was 41.1% using modified 
ATPIII criteria(40).  
 It is consistent with the study done by Aneemieke Ross et al(20) who 
reveals that free T4 was significantly associated with insulin resistance and 
with four out of five components of the metabolic syndrome (except glucose 
intolerance). The association of lower serum free thyroxine with metabolic 
syndrome is also proved by Lin SY et al. in chinese population(22).  
 The prevalence of the Metabolic syndrome increases as age advances. 
Above 40 yrs, 80.95% and 66.66% were Metabolic syndrome based on 
AHA/NHLBI (2005) criteria & IDF criteria respectively which was higher 
compared to the individuals below 30 (28.57% & 14.26% based on 
AHA/NHLBI (2005) criteria & IDF criteria respectively).  
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 Truncal obesity, elevated triglycerides, decreased HDL, hypertension 
and glucose intolerance were present in 43. 64%, 60%, 89.09%, 32.73% and 
47.27% of the study group respectively. Metabolic syndrome parameters 
were increased in study group than the general population.  
 Thyroid function could be one of several factors influencing the body 
weight in a population. Even slightly elevated serum TSH levels are 
associated with an increase in the occurrence of obesity (12). Leptin levels are 
decreased in the hypothyroid patients. Whether decreased leptin levels may 
contribute to the decreased energy expenditure in patients with 
hypothyroidism merits further investigation (52). 
 It was revealed in our study though 61.82% of patients are obese 
(BMI ≥ 25kg/m2) only 43. 64% was centrally obese (WC ≥ 80cm). Obese 
individuals were more in the study group compared to the centrally obese 
individuals indicating that hypothyroid influences obesity than central 
obesity.  
 Gupta et al found that truncal obesity was more in the population 
compared to the obesity (obesity in 50.3%, truncal obesity in 68.0 %( 41). In a 
study by Mohan et al. in industrial population it was found that by criteria 
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(body mass index ≥ 23 kg/m2) 60.2% was overweight (24). Ramachandran et 
al. in his study found out truncal obesity (WC≥ 85cms) was 31.4% in this 
region (40). It is obvious from this study, that hypothyroid patients are obese 
than centrally obese. Exact influence of thyroid hormone on the weight of 
individual in the era of sedentary life style and unbalanced diet needs further 
evaluation.  
 Elevated levels of total cholesterol, LDL cholesterol, and 
apolipoprotein are well documented features of overt hypothyroidism (58). 
Asvold et al. in HUNT Study (population based study) found the positive 
relationship of TSH within the reference range and serum lipid 
concentrations (57). Subclinical hypothyroid patients have increased serum 
lipid levels, and cholesterol levels appear to rise in parallel with serum 
TSH(7,34). The elevation of TGs in hypothyroidism is caused by a reduced 
removal rate of TG from plasma due to a decrease in the activity of hepatic 
TG lipase(54). Some studies have shown that hypothyroidism is associated 
with a lower HDL cholesterol level . Althaus et al. and Caron et al found a 
significantly lower HDL cholesterol fraction even in the subclinically 
hypothyroid patients(55,56). One rationale for treating subclinical 
hypothyroidism is to lower levels of LDL cholesterol and thereby 
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decrease atherosclerotic risk. Multiple small, randomized trials have been 
performed examining the effect of T4 treatment on lipid parameters in 
subclinical hypothyroidism, with the majority reporting a tendency toward 
beneficial effects, without achieving statistical significance(60). 
 Elevated total cholesterol (≥200mg), Hypertriglyceridemia (≥150 
mg), Reduced HDL (< 50mg), Elevated LDL (≥130) were present in 54.55% 
,60%, 89.09%, 43.64% of the study population respectively. Dyslipidemia 
was more in study group than the general population. Our study group had a 
significantly reduced HDL. 
Ramachandran et al. in his study found that reduced HDL(<40mg) is 
65.5% amongst urban Asian adults(40). In CUPS -5 study by Mohan et al. 
found that mean HDL cholesterol is low in our population (40 mg/dl)(89). 
Mohan et al. in another study in industrial population found that 
dyslipidaemia was prevalent in 40.2% of the study group. Hypertriglyceridaemia 
was seen in 28.3% of the study group(24); Gupta et al. revealed that elevated 
total cholesterol(≥ 200mg) in 45.8% and hypertriglyceridemia (≥ 150 mg)in 
28.6% of the urban female population in this region(41). 
 It is well known that Asian Indians have low HDL cholesterol levels, 
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which could be one of the risk factors for premature CAD in this ethnic 
group(90,91). Enas et al. in his study found dyslipidemia is prevalent in South 
Asia,which is characterized by high serum levels of apolipoprotein 
,triglycerides and low levels of apolipoprotein A1,high-density lipoprotein 
(HDL) cholesterol. In addition, the HDL particles are small, dense, and 
dysfunctional(87).  
 Subclinical hypothyroidism not started on levothyroxine in study 
group also had dyslipidemia. Hence subclinical hypothyroid should be 
treated in South Asia where dyslipidemia is widely prevalent to halt the 
progression of atherosclerosis. Whether hypothyroidism contributes to the 
dyslipidemia in this region merits further investigation.  
 In hypothyroidism,endothelial dysfunction and impaired VSM 
relaxation leads to increased SVR(78). These effects lead to diastolic 
hypertension in approximately 30% of patients, and thyroid hormone 
replacement therapy restores endothelial-derived vasorelaxation and blood 
pressure to normal in most patients(36). The increase in diastolic pressure 
occurs with low serum renin levels(81) and is a sodium sensitive form of 
hypertension(82). Asvold et al. in his study reports a linear correlation 
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between TSH and both systolic and diastolic blood pressure(14), whereas 
other studies do not find a correlation(17,31,83).  
 Luboshitzky et al(84) did observe that mean diastolic blood pressure 
was higher in subclinical hypothyroidism. Impaired endothelium-dependent 
vasodilatation as a result of a reduction in nitric oxide availability has been 
demonstrated in subclinical hypothyroidism as well(36).  
In our study hypertension was present in 32.73% of the study group , 
systolic and diastolic affecting equally. Mohan et al. in study found that 
overall crude prevalence of hypertension (HTN) in this population is 
21.1%(92). Mohan et al. in another study in industrial population found that 
hypertension is prevalent in 25.4%(24). Hypertension was more in our study 
group than the general population.  
 Glucose intolerance in hypothyroidism is not proved in latest studies 
though Shah et al. published insulin metabolism in hypothyroidism in 1975 
indicating that glucose intolerance of the hypothyroid state is not 
characterized by insulin resistance(85). Aneemieke Ross et al. in 2007 found 
that free T4 was significantly associated with insulin resistance and with 
four of five components of the metabolic syndrome (except glucose 
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intolerance(20).  
 In our study FBS (≥ 100mg) was 47.7% of the study group. It was 
increased compared to the general population. Ramachandran et al. in his 
study shows FPG(≥ 110mg) was present in 26.7% in the population(40). The 
National Urban Diabetes Survey (NUDS), carried out in six cities in the year 
2001, reported the age-standardized prevalence rates of diabetes was 12% in 
urban India](93). The age-standardized prevalence of diabetes in Chennai 
according to this study was 13.5 %. In addition the study also reported that 
14% had impaired glucose tolerance (IGT). The large population based 
study, CURES conducted on 26,001 individuals in the year 2001-2002, 
showed that according to the ADA criteria 19% had diabetes in Chennai and 
this scaled down to 16% when WHO criteria was used(94) India with its 
dubious distinction of being called, "the diabetic capital of the world" is 
presently estimated to have over 30 million individuals affected by this 
deadly disease.  
Though studies do not associate glucose intolerance with 
hypothyroidism, this was contrary to the prevalence of increased FBS in our 
study group. This association needs further evaluation.  
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In south east asia prevalence of diabetes, premature coronary artery 
disease and dyslipidemia are higher than the rest of the world though partly 
attributed due to genetic predisposition. Diabetes and premature coronary 
artery disease are occurring about 10 years earlier in south east asia than rest 
of the world population. In India, mortality attributable by CVD is expected 
to rise by 103% in men and by 90% in women from 1985 to 2015. HEART 
WATCH STUDY in 1995 and 2002 by Gupta et al. reveals that all 
modifiable risk factors(except hypertension in 36. 9vs. 33.7%) of CVD are 
increasing in women such as a) leisure time physical inactivity 72.4%  
vs 75.3%, b) obesity(BMI ≥ 25) 19.9%vs 39.4%,c) truncal obesity (waist:hip 
>0.8) 70.1 vs. 69.2%.d) tobacco use 18.7 vs.20.5%,e)diabetes history  
1.0 vs.7.3%.Same increasing trend is seen in males(95). 
Early diagnosis and aggressive management of modifiable risk factors 
like diabetes, hypertension, dyslipidemia, hypothyroidism, smoking, 
sedentary life style, dietary habits would halt this epidemic. Health 
education plays a vital role in the management. More prospective 
longitudinal follow up studies are required to throw light on association of 
hypothyroidism and metabolic syndrome in this region.  
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                         SUMMARY 
Patients with hypothyroidism are at increased risk of obesity, elevated 
triglyceride, decreased HDL and hypertension and may have increased risk 
of Metabolic syndrome.  
 A non randomized cross sectional Study was conducted in female 
primary hypothyroid patients who attended the EndocrinologyOPD,Institute 
of Internal Medicine, Madras Medical College and Government General 
Hospital,Chennai. The aim of the study was to find the prevalence of 
Metabolic Syndrome in frankly hypothyroid patients with poor drug 
compliance for more than 3 months, subclinical hypothyroidism not started 
on levothyroxine, recently diagnosed hypothyroid patient not started 
levothyroxine.  
 After applying inlusion and exclusion criteria, 55 female hypothyroid 
patients proved by thyroid hormone assay were selected for study after 
written consent. Detailed history including drug intake, clinical examination 
including anthropometric measurements were noted. After eight hours of 
fasting, blood drawn for fasting blood sugar and lipid profile.  22 patients 
 66
(40%) and 27 patients (49.09%) of the study group were diagnosed to be 
metabolic syndrome as per IDF criteria and AHA/NHLBI 2005 criteria 
respectively. Metabolic syndrome was increased in the study group than the 
general population. Majority were obese((BMI ≥ 25 kg/m2 - 61.82%) than 
centrally obese(WC ≥ 80 cms-43.64%). Elevated triglycerides, decreased 
HDL, hypertension and glucose intolerance were present in 60%, 89.09%, 
32.73% and 47.27% of the study group respectively. Though studies do not 
associate glucose intolerance with hypothyroidism, the factors causing 
increased FBS in this study group remain obscure. Incidence of Metabolic 
syndrome increases with age and this was also true in our study.  
 Subclinical hypothyroidism patients be treated in South East Asia 
where prevalence of diabetes, premature coronary artery disease and 
dyslipidemia are higher than the rest of the world. Affordable, accessible 
health care, health education including diet, exercise and drug compliance 
may halt the progression of diabetes, hypertension, obesity, premature 
coronary artery disease in this region  The study group consists of small 
number of subjects. The study concludes that larger prospective study has to 
be performed to confirm the association of hypothyroidism and Metabolic 
syndrome.  
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CONCLUSIONS 
1) Metabolic syndrome was increased in female frankly hypothyroid 
patients with poor drug compliance, subclinical hypothyroidism not 
started on levothyroxine, and newly diagnosed hypothyroid patient.  
2) Prevalence of Metabolic syndrome is 40% and 49. 09% as per IDF and 
AHA/NHLBI 2005 criteria respectively in the study group which was 
higher than the general Population.  
3) All the parameters of Metabolic syndrome like central obesity 
hypertension, decreased HDL, elevated triglycerides and glucose 
intolerance are increased in the study group. Majority of patients have 
generalized obesity rather than central obesity.  
4) All clinical and subclinical hypothyroid patients should be screened for 
metabolic syndrome parameters and if identified should be treated 
aggressively.  
5) Subclinical hypothyroidism should be treated in South East Asia where 
prevalence of diabetes, premature coronary artery disease and 
dyslipidemia are higher than the rest of the world though partly 
attributed due to genetic predisposition. 
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PROFORMA 
METABOLIC SYNDROME IN HYPOTHYROID PATIENTS 
Name  :      Age :   
 
Address :   
   
Exclusion Criteria 
 Male sex, pregnant women 
 Age below 21 years or above 55 years 
 Smoker, Alcoholic 
 Primary hypothyroid patient taking levothyroxine < 3 months 
 Severely ill patient 
 Patient taking medication for Diabetes, Hypertension, lipid disorder or 
taking steroids for any illness.  
 Known metabolic syndrome patients.  
THYROID PROFILE: 
Serum T3(Total) =     ng/ ml (0. 7-2. 0) 
Serum T4(Total) =     µg/dl ( 5. 5-13. 5) 
 Serum TSH        =      uIU/ml (0. 17-4. 05) 
Inference : Hypothyroidism - Present/Absent 
Serial No: 
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Height -      cms; Weight -  kgs; BMI-      Kg/m2 
Heart rate -      per min; Blood pressure -        mm Hg; 
AHA/NHLBI CRITERIA FOR METABOLIC SYNDROME: 
Three or more of the following five risk factors: 
•Central obesity 
Waist circumference for men >102 cm (> 40 in)Women >88 cm (>35 in) 
 Modified WC for south asians- Male ≥ 90 cm, Female ≥ 80 cms 
•Triglycerides ≥ 150 mg/dL (1. 7 mmol/L) 
• HDL cholesterol 
 Men < 40 mg/dL (1. 03 mmol/L) 
 Women < 50 mg/dL (1. 29 mmol/L) 
•Blood pressure ≥ 130/ ≥ 85 mm Hg 
•Fasting glucose ≥ 100 mg/dl 
 
 
IDF CRITERIA FOR METABOLIC SYNDROME: 
 
S. 
No CRITERIA REFERENCE VALUE 
PATIENT’S 
VALUE result 
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1.  
 
 
 
 
2.  
 
3.  
 
 
4.  
 
 
5.  
 
 
Central obesity defined 
as waist circumference 
for south asian male ≥ 90 
cm 
female≥ 80 cm 
Plus any two of the 
following four criteria  
Raised TG level ≥ 150 
mg/dL (1. 7 mmol/L), or 
specific treatment for this 
lipid abnormality 
Reduced HDL 
cholesterol < 40 mg/dL 
(1. 03 mmol/L) in males 
and < 50mg/dL (1. 29 
mmol/L) in females, or 
specific treatment for this 
lipid abnormality 
Raised blood pressure 
systolic BP ≥ 130 or 
diastolic BP ≥ 85 mm 
Hg, or treatment of 
previously diagnosed 
hypertension 
Raised fasting plasma 
glucose (FPG) ≥ 100 
mg/dL (5. 6 mmol/L), or 
previously diagnosed 
type 2 diabetes  
 
Male ≥ 90 cm 
Female≥ 80 cm 
  
 
 
≥ 150 mg/dL  
(1.7 mmol/L), 
 
Male <40mg/dl 
Female<50mg/
dl 
 
systolic BP ≥ 
130 or diastolic 
BP ≥ 85 mm 
Hg 
 
FPG≥100mg/d
L(5.6 mmol/L) 
 
 
Metabolic 
syndrome 
 
  Yes/No 
 
 
 
 
Yes/No 
 
Yes/No 
 
 
Yes/No 
 
 
Yes/No 
 
 
Present/
Absent 
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S.
N
O
Endo no Category Name  Age
S
e
x
Ht Wt HT 2 BMI T3 (ng/ml)
T4 
(µg/dl)
TSH 
uIu/ml)
Waist 
in cms TC
TG
(mg/dl)
HDL
(mg/dl) VLDL LDL SBP DBP FPG
A
T
P
I
D
F
1 6929/08 New Parvathi 55 F 151 56 2.28 24.6 0.32 28.5 44.1 86 120 285 40 57 23 134 86 76 4 Y
2 11092/07 Clinical Ratha 55 F   166 70 2.756 25.4 0.75 102 45.5 94 280 276 41 55.2 183.8 140 92 89 4 Y
3 8473/06 Clinical Amirthavalli 45 F 147 62 2.161 28.7 0.49 3.9 98.12 81 257 659 34 131.8 91.2 138 88 155 5 Y
4 6678/08 New Selvi 44 F 152 65 2.31 28.1 0.9 46.9 28.1 85 282 187 44 37.4 200.6 132 86 103 5 Y
5 1128/06 Clinical Mary 44 F 148 58 2.19 26.5 0.82 2.43 39.8 82 280 396 40 79.2 160.8 128 84 123 4 Y
6 3222/06 Clinical Kalaiselvi 35 F 154 70 2.372 29.5 0.9 7.28 18.08 92 232 395 42 79 111 124 78 115 4 Y
7 2416/06 Clinical Mahalakshmi 42 F 155 71 2.403 29.6 0.65 8.54 85.46 103 383 500 38 100 245 150 100 137 5 Y
8 378/07 Clinical Lakshmi 31 F 150 65 2.25 28.9 1.19 6.57 25.34 94 267 259 42 51.8 173.2 134 86 85 4 Y
9 7148/08 New Venkatalakshmi 39 F 150 55 2.25 24.4 0.3 41 55.4 87 199 357 37 71.4 90.6 144 90 103 5 Y
10 803/06 Clinical Susila 42 F 144 60 2.074 28.9 0.28 1.45 100 95 261 320 42 64 155 122 80 104 4 Y
11 7540/08 New Mohana 55 F 148 70 2.19 32 0.88 10.71 10.07 93 211 130 45 26 140 142 88 102 4 Y
12 7611/07 Clinical Susheela 50 F 142 54 2.016 26.8 0.5 55 14.5 79 160 107 54 21.4 84.6 136 86 82 1 N
13 9134/07 Clinical Selvalaxmi 29 F 150 61 2.25 27.1 0.61 4.35 12.02 78 210 189 39 37.8 133.2 120 80 89 2 N
14 4761/05 Clinical Mohana 38 F 145 55 2.103 26.2 0.64 8.12 40.18 79 200 155 45 31 124 128 82 85 2 N
15 2739/03 Clinical Yasoda 45 F 144 40 2.074 19.3 0.1 1.28 26.29 68 171 171 32 34.2 104.8 124 80 111 3 N
16 823/07 Clinical Mohana 35 F 153 58 2.341 24.8 0.74 1.52 102.27 75 220 134 43 26.8 150.2 110 70 81 1 N
17 3188/06 Clinical Ebsiba 21 F 143 40 2.045 19.6 0.33 3.07 44.15 65 183 109 31 21.8 130.2 112 72 105 2 N
18 4938/07 Clinical Dilsath 25 F 144 55 2.074 26.5 0.77 5.04 15.36 78 218 278 36 55.6 126.4 120 74 78 2 N
19 9152/07 Clinical Nagalakshmi 28 F 158 54 2.496 21.6 0.39 2.99 52.65 76 174 64 48 12.8 113.2 108 78 90 1 N
20 877/08 Clinical Shanthi 43 F 156 55 2.434 22.6 1.06 5 33.95 77 157 206 34 41.2 81.8 126 70 93 2 N
21 7089/06 Clinical Parvathi 25 F 148 62 2.19 28.3 0.73 5.43 83.06 76 150 110 42 22 86 120 70 65 1 N
22 3962/07 Clinical Damayanthi 45 F 148 65 2.19 29.7 0.45 4.15 31.85 91 266 187 51 37.4 177.6 130 86 82 3 Y
23 6079/08 New Dhanalakshmi 46 F 148 55 2.19 25.1 0.69 3.8 63.24 76 290 206 40 41.2 208.8 110 80 102 3 N
24 6813/08 New Vasanthi 28 F 147 46 2.161 21.3 0.43 0.3 150 77 181 152 45 30.4 105.6 114 78 96 2 N
25 6099/08 New Sudha 22 F 163 57 2.657 21.5 1.34 7.63 27.8 74 175 50 45 10 120 110 74 71 1 N
26 2185/05 Clinical Nirmala 31 F 152 55 2.31 23.8 0.21 1.52 99.61 76 275 75 48 15 212 114 78 90 1 N
27 4912/07 Clinical Kanagavalli 28 F 156 40 2.434 16.4 0.21 0.2 150 69 160 54 37 10.8 112.2 110 70 89 1 N
28 9600/07 Clinical Kanmani 24 F 148 45 2.19 20.5 0.69 3.91 17.32 70 152 111 41 22.2 88.8 112 72 98 1 N
29 4564/07 Clinical Sarasvathi 37 F 147 70 2.161 32.4 0.21 1.1 100 88 200 97 48 19.4 132.6 134 90 110 4 Y
30 7893/06 Clinical Nagamma 36 F 155 55 2.403 22.9 1.19 6.6 11.94 71 284 78 63 15.6 205.4 112 74 96 0 N
31 5036/08 New sumathy 27 F 155 66 2.403 27.5 0.56 91 13.2 79 218 228 46 45.6 126.4 120 80 119 3 N
32 4493/03 SubclinicalPappa 43 F 157 90 2.465 36.5 0.54 8.2 4.8 102 252 191 42 38.2 171.8 142 94 85 4 Y
33 10195/07 SubclinicalRukmani 43 F 152 65 2.31 28.1 1.38 4.35 5.65 90 184 131 41 26.2 116.8 140 90 130 4 Y
34 6736/08 New Chithra 21 F 145 76 2.103 36.1 0.45 94 9.59 98 231 341 35 68.2 127.8 110 72 161 4 Y
35 1077/07 SubclinicalZeenath 33 F 155 79 2.403 32.9 1.6 1.98 9.07 93 174 332 35 66.4 72.6 124 78 144 4 Y
36 4825/05 SubclinicalLakshmi 42 F 154 80 2.372 33.7 1.83 8.05 5.5 94 250 351 38 70.2 141.8 136 90 111 5 Y
37 4921/07 SubclinicalValli 50 F   153 55 2.341 23.5 0.8 7.12 5.17 81 169 222 40 44.4 84.6 134 88 118 5 Y
38 6765/05 SubclinicalShanthi 46 F   150 76 2.25 33.8 0.62 4.3 9.66 97 258 237 38 47.4 172.6 130 86 182 5 Y
39 1862/06 SubclinicalShanthi 40 F 155 65 2.403 27.1 1.06 7.74 6.78 88 205 155 40 31 134 126 78 93 3 Y
40 1088/07 SubclinicalNagalakshmi 27 F 157 85 2.465 34.5 0.91 4.08 5.78 99 302 80 40 16 246 120 72 189 3 Y
41 1112/07 SubclinicalVijaya 31 F 141 45 1.988 22.6 0.72 3.25 8.99 70 178 147 52 29.4 96.6 120 78 112 1 N
42 2720/08 New Datchayani 32 F 152 41 2.31 17.7 0.56 72 8.7 62 126 154 82 30.8 13.2 122 78 89 1 N
43 1055/03 SubclinicalVanathy 30 F 148 50 2.19 22.8 1.79 4.85 5.04 78 170 83 49 16.6 104.4 120 76 106 2 N
44 6643/08 New Sakunthala 30 F 148 58 2.19 26.5 1.41 152 9.17 79 160 237 33 47.4 79.6 124 80 90 2 N
45 4331/03 SubclinicalKarpagam 46 F 148 60 2.19 27.4 0.69 7.1 6.93 78 289 115 42 23 224 124 80 111 2 N
46 786/06 SubclinicalJayanthi 37 F 148 58 2.19 26.5 0.58 7.05 5.32 77 190 108 49 21.6 119.4 114 76 91 1 N
47 6721/08 New Ammani 37 F 148 40 2.19 18.3 0.46 121 6.47 69 186 84 42 16.8 127.2 130 86 94 2 N
48 4555/04 SubclinicalMythili 33 F 150 60 2.25 26.7 0.89 5.36 7.85 85 180 127 41 25.4 113.6 120 78 93 2 N
49 2821/08 New Lakshmi 34 F 146 40 2.132 18.8 1.13 5.6 6.71 58 118 87 33 17.4 67.6 116 80 80 1 N
50 7583/08 New Thulasi 29 F 146 51 2.132 23.9 1.37 6.3 7.55 74 154 182 45 36.4 72.6 100 72 93 2 N
51 5099/06 SubclinicalSasireka 34 F 155 60 2.403 25 0.52 4.4 6.17 77 253 327 46 65.4 141.6 120 80 99 2 N
52 6529/02 SubclinicalSelvi 24 F 143 50 2.045 24.5 0.58 15.19 9.29 74 203 176 48 35.2 119.8 120 70 112 3 N
53 6852/08 New Rathinamathi 33 F 147 60 2.161 27.8 0.55 91 9.87 83 290 200 50 40 200 122 80 95 2 N
54 4607/05 SubclinicalRajamani 43 F 152 58 2.31 25.1 1.75 3.84 8.48 78 220 163 35 32.6 152.4 134 88 101 4 N
55 7068/08 New sulpha 45 F 155 62 2.403 25.8 0.98 38.5 5.02 79 168 134 41 26.8 100.2 128 78 101 2 N
